Moreover, using mouse models it was shown that Rnf168 depletion protects against Brca1-mutated mammary tumorigenesis, and this data is further corroborated by the identification of a human genetic variant that reduces breast cancer risk in BRCA1-mutation carriers when they are associated with reduced RNF168 expression levels [164]. This evidence concerns the gene BRCA1 and breast carcinoma.